New white paper outlines how copays can benefit federally-funded prescription programs
In the world of copay programs, which are currently in the $5-billion range in total US industry funding and, by most accounts, continuing to rise, there are numerous hurdles between money that the biopharma industry would provide, and patients who can use the copays to offset out-of-pocket expenses. One of these hurdles is the limitation that they cannot be used for patients on Medicare, Medicaid or other publicly funded programs (HHS considers them to be an illegal financial inducement to patients). But an existing alternative, the so-called “charitable PAPs” (Prescription Assistance Programs) offer an alternative.
According to a white paper just published by HealthWell Foundation (Gaithersburg, MD), that organization has a "modified" authorization from the Office of Inspector General (OIG) of HHS—the only charitable PAP with this explicit modification, according to HealthWell—allowing it to establish Medicare-only funds. The primary requirement is that the assistance be offered for a disease state for which there are at least two medications, sold by two distinct manufacturers. Other charitable PAPs provide similar flexibility, but Healthwell promotes its programs as not only meeting legal requirements, but also being highly efficient in delivering assistance with minimal overhead.
Krista Zodet, VP at HealthWell, says that the Foundation is on track to meet its annual fundraising goals this year (last year it collected and disbursed $144 million), “but the need continues to rise” as copay requirements from insurers tighten, and millions continue to be un- or underinsured. Copay assistance continues to generate friction between industry and pharmacy benefit managers (PBMs), who look on the assistance as a way to get around the tier levels or formulary restrictions that they impose on health plans. But Zodet says that “we’re not involved” in that dispute; “in fact, we have insurance industry executives on our board and they have not expressed that concern.”
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.